Monthly Treatment Costs: Your Complete Financial Breakdown
Wegovy V Saxenda Monthly Cost Structure: Understanding Your Investment
The monthly cost comparison between Wegovy and Saxenda reveals distinct pricing patterns that reflect their different dosing schedules. Wegovy operates on a once-weekly injection system with a structured 16-week dose escalation, starting at £79.99 for the 0.25mg starter dose and progressing to £209.99 monthly for the 2.4mg maintenance dose. Saxenda, conversely, requires daily injections with a different cost structure that accumulates throughout each month. Both treatments are prescription-only medicines requiring clinical assessment through our GPhC-registered pharmacy (#9012878).
When evaluating Wegovy versus Saxenda monthly costs, consider the long-term financial commitment alongside clinical suitability. Wegovy's predictable monthly progression allows for clear budgeting across the dose escalation period, with maintenance costs stabilising at £209.99 monthly from week 17 onwards. Your prescriber can discuss which treatment structure aligns with your clinical profile and financial planning preferences during your consultation.
Wegovy Monthly Cost Breakdown: 16-Week Escalation to Maintenance
Wegovy's monthly cost progression follows a medically-supervised escalation designed to optimise tolerance whilst maintaining efficacy. Weeks 1-4 cost £79.99 monthly for the 0.25mg starter dose, progressing to £94.99 for the 0.5mg dose during weeks 5-8. The 1mg dose costs £99.99 monthly for weeks 9-12, followed by £139.99 for the 1.7mg dose during weeks 13-16. From week 17, the maintenance 2.4mg dose costs £209.99 monthly throughout continued treatment.
This structured approach to Wegovy versus Saxenda monthly cost comparison shows how the weekly injection schedule translates to predictable monthly expenses. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25 to access these prices. The escalation period totals approximately £624.96 over 16 weeks, with maintenance costs of £209.99 monthly thereafter for continued weight management support alongside a reduced-calorie diet and increased physical activity.
Saxenda V Wegovy: Daily Versus Weekly Cost Implications
Saxenda's daily injection requirement creates a different monthly cost pattern compared to Wegovy's weekly dosing schedule. Where Wegovy patients inject once weekly with clear monthly pricing, Saxenda requires 30 daily injections per month, affecting both convenience and cost structure. This fundamental difference in administration frequency significantly impacts the monthly financial commitment and practical management of your weight management treatment.
The Wegovy versus Saxenda monthly cost comparison extends beyond pure pricing to include practical considerations like injection frequency and pen longevity. Wegovy's FlexTouch pens provide 4 weekly doses per pen, whilst Saxenda pens contain multiple daily doses requiring more frequent replacements. Your prescriber can evaluate which dosing schedule aligns with your lifestyle and budget during your clinical assessment.
Clinical Evidence Supporting Wegovy V Saxenda Treatment Decisions
In clinical trials, patients taking Wegovy alongside diet and exercise achieved an average weight loss of ~15% at 68 weeks in the STEP 1 trial (Wilding et al., NEJM, 2021). The STEP programme demonstrated consistent weight management results across different patient populations, with the SELECT trial showing a 20% reduction in major cardiovascular events. These outcomes may help inform your treatment choice when comparing Wegovy versus Saxenda options with your prescriber.
Saxenda clinical trials demonstrate different efficacy patterns, with treatment outcomes varying based on individual patient factors and adherence to daily injection schedules. Both medications work through GLP-1 receptor agonism but with different dosing frequencies that may influence long-term treatment success and monthly cost considerations.
How Wegovy Works: GLP-1 Mechanism for Weight Management
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone regulating appetite and blood sugar levels. This medication may help reduce appetite by acting on brain centres controlling hunger signals, potentially promoting feelings of fullness after smaller meals. The weekly injection schedule maintains consistent medication levels throughout each month, supporting sustained appetite regulation. GLP-1 receptor activation may also slow gastric emptying, extending satiety between meals and supporting portion control efforts. These mechanisms work alongside lifestyle modifications to support weight management goals throughout your treatment journey.
EverydayMeds Ordering Process: From Assessment to Delivery
Accessing Wegovy through EverydayMeds begins with our 3-minute online clinical assessment, evaluating your suitability for weight management treatment. Our prescribers review your application within 3 working days (or 24 hours with express service), ensuring appropriate clinical oversight for this prescription-only medicine. Once approved, your monthly Wegovy supply ships via next-day cold-chain delivery, maintaining the 2-8°C storage requirements essential for medication efficacy. Our temperature-controlled logistics ensure your monthly treatment arrives in optimal condition, supporting uninterrupted dose escalation or maintenance therapy. This streamlined process eliminates clinic visits whilst maintaining full clinical safety standards under our GPhC registration (#9012878).
Storage Advantages: Wegovy V Saxenda Practical Considerations
Wegovy offers superior storage flexibility compared to many weight management medications, remaining stable for 6 weeks at room temperature below 30°C once removed from refrigeration. This storage advantage supports travel, work schedules, and lifestyle flexibility whilst maintaining monthly treatment consistency. Each FlexTouch pen provides 4 weekly doses, requiring refrigeration at 2-8°C before first use but offering extended room temperature stability thereafter. The weekly injection schedule means fewer pen changes per month compared to daily injection alternatives, simplifying storage management and reducing monthly handling requirements. Proper storage ensures optimal medication potency throughout your monthly treatment cycle, supporting consistent weight management results.
Wegovy Versus Saxenda Monthly Budget Planning Strategies
Effective budget planning for Wegovy v Saxenda monthly costs requires understanding the escalation phase financial commitment alongside maintenance dose expenses. The initial 16-week period represents an investment in treatment optimisation, with costs gradually increasing as doses escalate to the therapeutic 2.4mg level. Many patients find budgeting easier with Wegovy's predictable weekly schedule compared to daily injection alternatives requiring more frequent pen replacements.
Annual cost planning for Wegovy maintenance therapy totals approximately £2,519.88 (£209.99 × 12 months), excluding the initial escalation period. This long-term perspective helps compare Wegovy versus Saxenda total treatment costs when planning your weight management investment. Consider that weight management is typically a long-term commitment, with treatment costs representing an investment in health outcomes that may reduce future healthcare expenses.
Accessing Wegovy V Saxenda Through EverydayMeds: Your Next Steps
Both Wegovy and Saxenda are available through EverydayMeds, with your prescriber helping determine which treatment aligns with your clinical needs and monthly budget considerations. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25 to access our competitive monthly pricing structure. Our clinical team ensures appropriate treatment selection based on your individual circumstances, supporting informed decisions about Wegovy versus Saxenda options. Visit https://everydaymeds.co.uk/collections/wegovy to begin your assessment and compare monthly costs for both treatments. Start your weight management journey with transparent pricing, expert clinical oversight, and the convenience of next-day delivery from our GPhC-registered pharmacy.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
